Development of a wearable telemetry module and dual hormone infusion set for use
Development of a wearable telemetry module and dual hormone infusion set for use
批准号:
8633242
负责人:
Robert S Cargill
金额:
$22.27万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-19 至 2015-08-31
关键词:
AnodesArtificial Endocrine PancreasArtificial PancreasB-insulinBackBerylliumCathetersChemicalsClinicalCommunicationComplexComputer softwareDataDevelopmentDevicesDiabetes MellitusElectrodesElectronicsElementsFamily suidaeFreedomFundingGlucagonGlucoseHormonesHousingInfectionInfusion proceduresInsulinInsulin Infusion SystemsInsulin-Dependent Diabetes MellitusLeftLiquid substanceMicrodialysisMicrofabricationMovementNon-Insulin-Dependent Diabetes MellitusPatientsPerfusionPharmaceutical PreparationsPhasePumpQuality of lifeResearchRiskSignal TransductionSiteSkinStagingStreamStructureSystemTechniquesTechnologyTelemetryTelephoneTestingTimeTouch sensationTubeWireless Technologyanalogcostdata acquisitiondata exchangedesignflexibilityglucose monitorglucose sensornovelpressureprototypepublic health relevancesealsensorsolid statesubcutaneouswasting
中文摘要
描述(由申请人提供):1型糖尿病通常会导致短期和长期并发症,影响生活质量。虽然许多研究小组正在开发人工内分泌胰腺(AP)系统的版本,但目前的系统需要至少一个激素递送插入位点和至少一个葡萄糖传感器位点。这种复杂性限制了商业可行性和患者的潜在接受度。多个插入部位的细菌定植和感染风险值得减少插入器械的数量。 在这个项目中,我们提出创建一种新颖的人工胰腺技术,该技术将以下三个元素集成到单个可穿戴设备中:(1)智能激素输送导管,其外壁包含多位点电流式连续葡萄糖监测器(CGM),其开发由其他地方资助;(2)无线传感器模块,具有收发器,电池和数据采集单元;以及(3)连接到传感导管和胰岛素输送管连接器的快速连接/断开端口。该组合器械旨在允许更多的运动自由度并提高患者舒适度。我们更喜欢皮下部位而不是皮内部位进行传感和激素输送,因为导管移位的风险较低。为了避免需要灌注和废液室,我们更喜欢直接安培法微透析。 在一个单独的项目中,我们正在使用固态设计和微制造技术,通过将平面电流传感阵列放置在柔性聚酰亚胺基板上来创建传感导管,然后将其包裹成管。在该应用中,我们建议开发统一的可穿戴设备,以允许临床使用传感导管。这款由三部分组成的设备将连接到胰岛素输注管路,并将包括模拟传感器电气接口和蓝牙SMART收发器。该组合将允许商业引入智能输液器,该输液器可以连接到仅胰岛素泵或胰岛素/胰高血糖素泵,例如由JDRF资助的Tandem Diabetes正在开发的胰岛素/胰高血糖素泵。该胰岛素泵可能包含能够与我们的传感器模块通信的蓝牙无线接口。我们还建议创建一个早期的原型插入装置,并在猪身上进行系统的初步测试。在这些试验中,将带有传感导管的三部分器械皮下插入麻醉猪体内,以便(1)对导管插入角度和深度进行射线照相评估;(2)验证遥测数据传输至远程智能手机接收器;以及(3)胰岛素无泄漏输送。猪的研究成本将在很大程度上
覆盖在其他地方。
英文摘要
DESCRIPTION (provided by applicant): Type 1 diabetes often leads to short-term and long-term complications which impair quality of life. Though many research groups are developing versions of an artificial endocrine pancreas (AP) system, current systems require at least one hormone delivery insertion site and at least one glucose sensor site. This complexity limits commercial viability and potential acceptance by patients. The risk of bacterial colonization and infection from the multiplicity of insertion sites merits reduction of the number of inserted devices. In this project, we propose to create a novel artificial pancreas technology that integrates into a single wearable device the following three elements: (1) an intelligent hormone delivery catheter whose outer wall contains a multi-site amperometric continuous glucose monitor (CGM), the development of which is funded elsewhere; (2) a wireless sensor module with a transceiver, battery, and data acquisition unit; and (3) a quick connect/disconnect port that attaches to the sensing catheter and to an insulin delivery tubing connector. This combination device is intended to allow more freedom of movement and increase patient comfort. We prefer the subcutaneous site over the intradermal site for sensing and hormone delivery because of a lower risk for catheter dislodgement. In order to avoid the need for perfusion- and waste fluid compartments, we prefer direct amperometry over microdialysis. In a separate project, we are using solid state design and microfabrication techniques to create the sensing catheter by placing a flat amperometric sensing array on a flexible polyimide substrate which will then be wrapped into a tube. In this application, we propose to develop the unified wearable device that will allow clinical use of the sensing catheter. This three-part device will connect to an insulin delivery line and will include an analog sensor electrical interface and a Bluetooth SMART transceiver. The combination will permit the commercial introduction of an intelligent infusion set that can connect to an insulin-only pump or an insulin/glucagon pump such as the one under development by Tandem Diabetes as funded by JDRF. This pump will likely incorporate a Bluetooth wireless interface capable of communication with our sensor module. We also propose to create an early prototype insertion device and carry out preliminary tests of the system in swine. In these tests, the three-part device with sensing catheter will be inserted subcutaneously into anesthetized pigs in order to allow (1) radiographic assessment of the catheter insertion angle and depth; (2) verification of telemetric data transmission to a remote smart phone receiver; and (3) leak-free delivery of insulin. Pig study costs will largely be
covered elsewhere.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
An Amperometric Glucose Sensor Integrated into an Insulin Delivery Cannula: In Vitro and In Vivo Evaluation.
集成到胰岛素输送插管中的电流式葡萄糖传感器:体外和体内评估。
DOI:
10.1089/dia.2016.0407
发表时间:
2017
期刊:
Diabetes technology & therapeutics
影响因子:
5.4
作者:
[Ward,WKenneth, Heinrich,Gabriel, Breen,Matthew, Benware,Sheila, Vollum,Nicole, Morris,Kristin, Knutsen,Chad, Kowalski,JosephD, Campbell,Scott, Biehler,Jerry, Vreeke,MarkS, Vanderwerf,ScottM, Castle,JessicaR, Cargill,RobertS]
通讯作者:
Cargill,RobertS
Development of a miniaturized, single-port automated insulin delivery system utilizing a glucose sensing catheter, ultra-concentrated insulin, and an optimized control algorithm
-
批准号:9898915
-
项目类别:
-
资助金额:$29.96万
-
财政年份:2019
-
负责人:Robert S Cargill
-
依托单位:
海外基金